Abstract
SARS-CoV2 might conduce to rapid respiratory complications challenging healthcare systems worldwide. Immunological mechanisms associated to SARS-CoV2 infection are complex and not yet clearly elucidated. Arguments are in favour of a well host-adapted virus. Here I draw a systemic immunological representation linking actual SARS-CoV2 infection literature that hopefully might guide healthcare decisions to treat COVID-19. I suggest HLA-G and HLA-E, non classical HLA class I molecules, in the core of COVID-19 complications. These molecules are powerful in immune tolerance and might inhibit/suppress immune cells functions during SARS-CoV2 infection promoting virus subversion. Dosing soluble forms of these molecules in COVID-19 patients’ plasma might help the identification of critical cases. I recommend also developing new SARS-CoV2 therapies based on the use of HLA-G and HLA-E or their specific receptors antibodies in combination with FDA approved therapeutics to combat efficiently COVID-19.
Keywords: COVID-19; HLA-E; HLA-G; NKG2A; SARS-CoV2.
【저자키워드】 COVID-19, HLA-G, SARS-CoV2., HLA-E, NKG2A, 【초록키워드】 SARS-CoV2, therapy, antibody, Respiratory complications, HLA-G, FDA, virus, SARS-CoV2 infection, COVID-19 complications, healthcare, immune cells, plasma, receptor, respiratory, mechanism, function, Dosing, Combination, HLA-E, NKG2A, Immune cell, HLA class I, COVID-19 patient, critical cases, Healthcare system, Healthcare systems, immune tolerance, complex, help, treat, core, argument, HLA class I molecules, immunological, classical, form, approved, respiratory complication,